MX2021009199A - Conjugado de farmaco de dos ligandos y uso del mismo. - Google Patents
Conjugado de farmaco de dos ligandos y uso del mismo.Info
- Publication number
- MX2021009199A MX2021009199A MX2021009199A MX2021009199A MX2021009199A MX 2021009199 A MX2021009199 A MX 2021009199A MX 2021009199 A MX2021009199 A MX 2021009199A MX 2021009199 A MX2021009199 A MX 2021009199A MX 2021009199 A MX2021009199 A MX 2021009199A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutically acceptable
- drug conjugate
- acceptable salt
- ligand drug
- conjugate compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
La presente divulgación divulga un compuesto de conjugado o una sal farmacéuticamente aceptable del mismo, que comprende una carga útil y dos moléculas de dirección. Se divulga además en este documento una composición farmacéutica, que comprende el compuesto de conjugado o la sal farmacéuticamente aceptable del mismo. La presente divulgación se refiere adicionalmente a un método para suministrar una carga útil a un sujeto que lo necesita, y un método para tratar una enfermedad, en el que los métodos comprenden administrar al sujeto una cantidad terapéuticamente eficaz del compuesto de conjugado o la sal farmacéuticamente aceptable del mismo, o la composición farmacéutica como se divulga en este documento.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2019073962 | 2019-01-30 | ||
CN202010048593 | 2020-01-16 | ||
PCT/CN2020/074117 WO2020156513A1 (zh) | 2019-01-30 | 2020-01-31 | 双配体药物偶联体及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021009199A true MX2021009199A (es) | 2021-09-08 |
Family
ID=71840373
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021009199A MX2021009199A (es) | 2019-01-30 | 2020-01-31 | Conjugado de farmaco de dos ligandos y uso del mismo. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220175761A1 (es) |
EP (1) | EP3903825A4 (es) |
JP (1) | JP2022518924A (es) |
KR (1) | KR20210119413A (es) |
CN (1) | CN113453720A (es) |
AU (1) | AU2020214507A1 (es) |
BR (1) | BR112021015109A2 (es) |
IL (1) | IL285148A (es) |
MX (1) | MX2021009199A (es) |
SG (1) | SG11202108182RA (es) |
TW (1) | TW202100183A (es) |
WO (1) | WO2020156513A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022099762A1 (zh) * | 2020-11-12 | 2022-05-19 | 博瑞生物医药(苏州)股份有限公司 | 一种抗体偶联物中间体及其制备方法 |
AU2022296571A1 (en) * | 2021-06-25 | 2023-12-14 | Coherent Biopharma (Suzhou) , Limited | Ligand-drug conjugate and use thereof |
US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
CA3235106A1 (en) * | 2021-10-19 | 2023-04-27 | Sixiang FAN | Conjugate pharmaceutical preparation, preparation method therefor and use thereof______________ |
TW202404643A (zh) * | 2022-04-20 | 2024-02-01 | 大陸商同宜醫藥(蘇州)有限公司 | 化合物及用途 |
TW202400140A (zh) * | 2022-04-27 | 2024-01-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合 |
CN116789733A (zh) * | 2022-07-05 | 2023-09-22 | 上海药明合联生物技术有限公司 | 偶联连接子 |
WO2024051794A1 (zh) * | 2022-09-09 | 2024-03-14 | 同宜医药(苏州)有限公司 | 放射性核素偶联药物及其药物组合物和应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006093991A1 (en) | 2005-03-02 | 2006-09-08 | The Cleveland Clinic Foundation | Compounds which bind psma and uses thereof |
HRP20221195T1 (hr) | 2009-03-19 | 2022-12-09 | The Johns Hopkins University | Spojevi koji ciljaju psma i njihova uporaba |
CN106466484B (zh) * | 2015-08-11 | 2021-05-04 | 同宜医药(苏州)有限公司 | 一种具有细胞内吞介导功能的多靶向配体-药物偶联体 |
CN106433063A (zh) | 2015-08-12 | 2017-02-22 | 普立万聚合体(上海)有限公司 | 含有蓝光阻隔添加剂的混合物 |
CN107412794B (zh) * | 2017-04-17 | 2019-01-04 | 中国医学科学院北京协和医院 | 双靶点显像分子探针及其制备方法和应用 |
CN107970453A (zh) * | 2017-12-05 | 2018-05-01 | 北京林业大学 | 一种叶酸修饰的果胶纳米粒子的双靶向递送方法 |
-
2020
- 2020-01-31 JP JP2021543527A patent/JP2022518924A/ja active Pending
- 2020-01-31 US US17/426,293 patent/US20220175761A1/en active Pending
- 2020-01-31 AU AU2020214507A patent/AU2020214507A1/en active Pending
- 2020-01-31 WO PCT/CN2020/074117 patent/WO2020156513A1/zh active Application Filing
- 2020-01-31 SG SG11202108182RA patent/SG11202108182RA/en unknown
- 2020-01-31 MX MX2021009199A patent/MX2021009199A/es unknown
- 2020-01-31 BR BR112021015109A patent/BR112021015109A2/pt unknown
- 2020-01-31 CN CN202080011608.8A patent/CN113453720A/zh active Pending
- 2020-01-31 EP EP20748044.3A patent/EP3903825A4/en active Pending
- 2020-01-31 KR KR1020217024254A patent/KR20210119413A/ko unknown
- 2020-05-14 TW TW109115998A patent/TW202100183A/zh unknown
-
2021
- 2021-07-27 IL IL285148A patent/IL285148A/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112021015109A2 (pt) | 2022-01-11 |
SG11202108182RA (en) | 2021-08-30 |
WO2020156513A1 (zh) | 2020-08-06 |
EP3903825A1 (en) | 2021-11-03 |
CN113453720A (zh) | 2021-09-28 |
JP2022518924A (ja) | 2022-03-17 |
IL285148A (en) | 2021-09-30 |
KR20210119413A (ko) | 2021-10-05 |
US20220175761A1 (en) | 2022-06-09 |
EP3903825A4 (en) | 2023-01-11 |
TW202100183A (zh) | 2021-01-01 |
AU2020214507A1 (en) | 2021-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021009199A (es) | Conjugado de farmaco de dos ligandos y uso del mismo. | |
EP4306523A3 (en) | Imidazoquinoline compounds and uses thereof | |
MY196599A (en) | Pharmaceutical compositons comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine | |
MX2019012884A (es) | Terapia de combinacion. | |
MX2022015695A (es) | Medicina de camptotecina con alta unidad de conexion hidrofila y conjugado de la misma. | |
PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
PH12020551425A1 (en) | Rimegepant for cgrp related disorders | |
EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
MX2021005651A (es) | Combinacion farmaceutica para el tratamiento contra el cancer. | |
MX2018005715A (es) | Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash. | |
MX2021015543A (es) | Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo. | |
MX2022000430A (es) | Administracion de agonista de sting e inhibidores de puntos de control. | |
MX2021009539A (es) | Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina. | |
AU2018282104A1 (en) | Use of vibegron to treat overactive bladder | |
MX2022000143A (es) | Metodos novedosos. | |
MX2020007971A (es) | Composiciones y metodos para tratar edema pulmonar o inflamacion pulmonar. | |
MX2022007911A (es) | Procedimiento de tratamiento de una infeccion virica usando un agonista de tlr7. | |
BR112021025531A2 (pt) | Moduladores de pirazol-piridona farmacêuticamente ativos da nedilação de cullin mediada por dcn1/2 | |
JP2016505050A5 (es) | ||
GB2590189A9 (en) | Lycorine derivatives, pharmaceutical composite thereof and usage therefor | |
MY193963A (en) | Composition for treating joint diseases and kit containing same | |
AU2018260628A1 (en) | Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions | |
EA201991069A1 (ru) | Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом | |
EP3972432A4 (en) | PHARMACEUTICAL FORMULATIONS AND METHODS FOR DELIVERING A THERAPEUTIC, DIAGNOSTIC OR CONTRAST AGENT TO CD206 | |
MX2022012001A (es) | Tratamiento preventivo de la migra?a. |